These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 12097261)

  • 1. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.
    Adam BL; Qu Y; Davis JW; Ward MD; Clements MA; Cazares LH; Semmes OJ; Schellhammer PF; Yasui Y; Feng Z; Wright GL
    Cancer Res; 2002 Jul; 62(13):3609-14. PubMed ID: 12097261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.
    Qu Y; Adam BL; Yasui Y; Ward MD; Cazares LH; Schellhammer PF; Feng Z; Semmes OJ; Wright GL
    Clin Chem; 2002 Oct; 48(10):1835-43. PubMed ID: 12324514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic potential of serum proteomic patterns in prostate cancer.
    Bañez LL; Prasanna P; Sun L; Ali A; Zou Z; Adam BL; McLeod DG; Moul JW; Srivastava S
    J Urol; 2003 Aug; 170(2 Pt 1):442-6. PubMed ID: 12853795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer.
    Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; Yang BX; He DC; Zhao XJ
    Asian J Androl; 2006 Jan; 8(1):45-51. PubMed ID: 16372118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
    Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
    J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
    Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
    Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].
    Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; He DC; Zhao XJ; Yang BX
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3172-5. PubMed ID: 16405834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correspondence re: B-L. Adam et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res., 62: 3609-3614, 2002.
    Stattin P; Hakama M
    Cancer Res; 2003 May; 63(10):2701; author reply 2701-2. PubMed ID: 12750300
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tree analysis pattern of mass spectral urine profiles in differential diagnosis of bladder transitional cell carcinoma].
    Wu DL; Zhang YF; Guan M; Liu WW; Xu YM; Jin SB; Zhang J; Jin CR; Lü Y
    Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):274-7. PubMed ID: 17760254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient.
    Zhang YF; Wu DL; Guan M; Liu WW; Wu Z; Chen YM; Zhang WZ; Lu Y
    Clin Biochem; 2004 Sep; 37(9):772-9. PubMed ID: 15329315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.
    Cazares LH; Adam BL; Ward MD; Nasim S; Schellhammer PF; Semmes OJ; Wright GL
    Clin Cancer Res; 2002 Aug; 8(8):2541-52. PubMed ID: 12171882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma.
    Ho DW; Yang ZF; Wong BY; Kwong DL; Sham JS; Wei WI; Yuen AP
    Cancer; 2006 Jul; 107(1):99-107. PubMed ID: 16708360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
    Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
    Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
    Liu J; Zheng S; Yu JK; Zhang JM; Chen Z
    J Zhejiang Univ Sci B; 2005 Jan; 6(1):4-10. PubMed ID: 15593384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
    Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
    Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.
    Giskeødegård GF; Hansen AF; Bertilsson H; Gonzalez SV; Kristiansen KA; Bruheim P; Mjøs SA; Angelsen A; Bathen TF; Tessem MB
    Br J Cancer; 2015 Dec; 113(12):1712-9. PubMed ID: 26633561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.
    Al-Ruwaili JA; Larkin SE; Zeidan BA; Taylor MG; Adra CN; Aukim-Hastie CL; Townsend PA
    Cancer Genomics Proteomics; 2010; 7(2):93-103. PubMed ID: 20335524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses.
    Jayapalan JJ; Ng KL; Razack AH; Hashim OH
    Electrophoresis; 2012 Jul; 33(12):1855-62. PubMed ID: 22740474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.